By safeguarding the BBB, SGLT-2 inhibitors may prevent the influx of harmful substances into the brain, thus reducing the risk of neurodegeneration and cognitive decline in patients with diabetes. This evidence concerns the gene SLC5A2 and Mental deterioration.